Cellply Fringe Event: Session 6

Cellply Fringe Event: Session 6

Friday, January 19, 2024 8:15 AM to 9:00 AM · 45 min. (US/Eastern)
Fringe Event
Presentation
Exhibitor Booth 427

Information

08:15 – 08:30 Measurement And Optimization Of Potency And Fitness Of Novel TCR-T Cell Therapies, Using Single-Cell Cytotoxicity Analysis.

  • Frequency of serial killer cells as an indicator of enhanced T-cell fitness in novel TCR-T cells engineered with innovative DNA nanovectors
  • Evaluating the effect of donor heterogeneity and the impact of vector composition on therapeutic potency using a unified potency score

Richard Harbottle, Head of DNA Vector Research, German Cancer Research Centre (DKFZ)


8.30 - 8.45 Break


08:45 – 09:00 A Novel Unified Potency Score, From Single-Cell Functional Profiles, Enables Direct Comparability Of Cell-Based Therapeutic Candidates

  • Use of potency score to compare strategies to boost potency, from cell engineering to selection of subpopulations of serial killer cells to combination therapies with engagers
  • Use of potency score to accelerate process development and optimise process parameters to achieve target potency

Massimo Bocchi, Chief Strategy Officer, Cellply

Cellply427Cellply - Unravelling immune system function, one cell at a time. Functional profiling at single cell resolution within a heterogenous cell population offers a unique signature into cellular interactions. Our powerful, fully automated VivaCyte platform delivers in-depth comprehensive characterization of immune cell function for cytotoxicity, serial killing and cytokine secretion assays in combination with phenotypic analysis. Employing propriety co-culture array technology and AI informed imaging, our multi-parametric single-cell analysis provides actionable insights across research and development. VivaCyte offers a dramatically improved level of understanding of immunotherapy mode of action, including determination of relative potency.

Log in